当归补血汤对HIV/AIDS合并淋巴瘤化疗后患者免疫功能和生活质量的影响  

Effect of Danggui Buxue Decoction on immune function and quality of life in patients with HIV/AIDS with lymphoma after chemotherapy

作　　者：张维 李奇穗[1] 邓长刚 黄薇 孙艳雨 袁婧[1] ZHANG Wei;LI Qisui;DENG Changgang;HUANG Wei;SUN Yanyu;YUAN Jing(Infectious Disease Department,Chongqing Public Health Medical Center,Chongqing 400036,China)

机构地区：[1]重庆市公共卫生医疗救治中心感染科,重庆400036

出　　处：《中国艾滋病性病》2025年第1期40-44,共5页Chinese Journal of Aids & STD

基　　金：重庆市首批公共卫生重点学科;重庆市科卫中医药技术创新与应用发展项目(2022QNXM076);重庆市卫生健康委中医药科研项目(2024 WSJK147)。

摘　　要：目的探讨当归补血汤对HIV/AIDS合并淋巴瘤化疗后患者免疫功能、生活质量的影响。方法采用前瞻性研究方法,将入组患者采用随机数字表法分为对照组和治疗组。两组患者均根据《2021年CSCO淋巴瘤诊疗指南》制定化疗方案,以21天为1个周期,连续4个周期方案。治疗组在对照组的基础上加用当归补血口服液,比较两组患者入组时的基线情况、病理分型、分期,治疗后两组CD4细胞、CD8细胞、CD4/CD8细胞比值、生活质量(即ECGO评分)、两组患者不良反应发生情况。结果本研究共纳入64例HIV/AIDS合并淋巴瘤化疗后患者,治疗组、对照组各32例;平均年龄(52.30±1.51)岁,以男性为主,占92.19%(59/64)。两组患者入组时在年龄、性别、吸烟史、饮酒史、感染途经、是否规范抗HIV治疗、CD4细胞、HIV RNA、病理类型分布、分期方面比较差异均无统计学意义(P均>0.05)。治疗后,CD4细胞、CD4/CD8细胞比值治疗组高于对照组(142.44±95.50 vs.90.13±48.91,0.46±0.32 vs.0.21±0.10),ECGO评分在0~1分组占比治疗组高于对照组(65.63%vs.15.63%),在2、3~4分组占比对照组高于治疗组(59.37%vs.28.12%,25.00%vs.6.25%),不良反应发生情况方面,粒细胞<0.5×10^(9)/L、血红蛋白≤60 g/L、血小板<50×10^(9)/L治疗组占比低于对照组(37.50%vs.75.00%,40.63%vs.15.63%,68.75%vs.37.50%),以上两组比较差异均有统计学意义(P均<0.05)。结论当归补血汤可以提升HIV/AIDS合并淋巴瘤化疗后患者的CD4细胞、CD4/CD8细胞比值等免疫指标,改善生活质量,减轻化疗后骨髓抑制程度,对治疗有积极的影响。Objective To investigate the impact of Danggui Buxue Decoction on immune function and quality of life(QoL)in patients with HIV/AIDS with lymphoma after chemotherapy.Methods In this prospective study,enrolled patients were randomly assigned to either a control or treatment group using a random number table.Both groups received chemotherapy regimens according to the 2021 CSCO Lymphoma Diagnosis and Treatment Guidelines,with a 21 days cycle for four consecutive cycles.The treatment group received Danggui Buxue oral liquid in addition to the standard chemotherapy in the control group.Baseline characteristics,pathological classification,staging,and post-treatment outcomes,including CD4 and CD8 T-cell counts,CD4/CD8 ratio,QoL ECGO(Eastern Cooperative Oncology Group)score,and adverse events were compared between the two groups.Results A total of 64 patients with HIV/AIDS with lymphoma who underwent chemotherapy were enrolled,with 32 patients in each group.The mean age was 52.30±1.51 years,and the majority were male(92.19%,59/64).No significant differences were found between the two groups at baseline in terms of age,sex,smoking and drinking history,transmission route,adherence to antiretroviral therapy,CD4 cell count,HIV RNA levels,pathological type distribution,or stage(P>0.05).After treatment,the treatment group showed significantly higher CD4 cell counts and CD4/CD8 ratio compared to the control group(142.44±95.50 vs.90.13±48.91,0.46±0.32 vs.0.21±0.10).Additionally,a higher proportion of patients in the treatment group scored 0-1 on the ECGO scale(65.63%vs.15.63%),whereas a higher proportion in the control group scored 2 and 3-4(59.37%vs.28.12%,25.00%vs.6.25%,respectively).Regarding adverse events,the treatment group had a lower count of granulocyte at<0.5×10^(9)/L,hemoglobin level≤60 g/L,and platelet<50×10^(9)/L compared to the control group(37.50%vs.75.00%,40.63%vs.15.63%,68.75%vs.37.50%,respectively),with statistically significant differences(P<0.05).Conclusions The Danggui Buxue Decoction can improve imm

关 键 词：当归补血汤 艾滋病病毒 艾滋病 淋巴瘤 免疫功能 生活质量 

分 类 号：R512.91[医药卫生—内科学] R373.9[医药卫生—临床医学]